Beijing Centergate: China regulator approves clinical trial of BDB tablets for hypertension
Beijing Centergate Technologies said China's NMPA has approved a clinical trial for its unit's BDB tablets, intended for hypertension treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Beijing Centergate: NMPA Approves Clinical Trial of BDB Tablets for Hypertension
Beijing Centergate Technologies Holding Co Ltd (SZSE:000931) announced that the NMPA has approved the clinical trial of its BDB Tablets for hypertension.